In a landmark phase II study, semaglutide demonstrated NASH resolution without worsening of fibrosis in 36 to 59% of patients with liver fibrosis, compared with only 17% in the placebo group
Likewise, comparison between Gipr fl/fl vehicle-treated and Gipr Syn/ vehicle-treated groups demonstrated negative enrichment in cholesterol biosynthesis, ECM and collagen organization, and immune response and inflammation pathways (Fig
Su aplicacin debe realizarse siempre segn el protocolo de trabajo del profesional y conforme al uso previsto del producto
Knowing exactly where and how to tap into the right key drivers highlights a path to launch success in modern markets
in turn, their liver health had improved, on average. 4
Acknowledgements The authors would like to thank Thomas Rohban, MD, and Magalie El Hajj, PharmD, from Partner 4 Health (Paris, France) for providing medical writing support in accordance with Good Publication Practice (GPP3) guidelines